Kiromic Biopharma
Houston
About Kiromic Biopharma
Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. Their cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $63.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2022)
- Ticker: nasdaq:KRBP
- Website: kiromic.com
- Phone: 806-252-5845
Industries & Categories
Bioinformatics, Biopharma, Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/kiromic-biopharma-178980 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.